FLAGSHIP IS PRESENTING A POSTER AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 34TH ANNUAL MEETINGNovember 6-10, 2019 Gaylord National Hotel and Convention Center, National Harbor, MD Flagship is presenting a scientific poster on November 8th at the meeting in...
WEBINAR – IMPROVING PD-L1 SCORING WITH IMAGE ANALYSISOctober 9, 2019 1 PM EDT/10 AM PDT on “Improving PD-L1 Scoring with Image Analysis”.
ANALYTICAL ADVANCEMENTS TO POWER BIOMARKER DEVELOPMENT TRACK PRESENTATION: ADDING VALUE TO TRADITIONAL IN VITRO DIAGNOSTICS (IVDS) AT WORLD CB&CDXSeptember 12, 2019 at 2:50pm The Renaissance Boston Waterfront, Boston, MA Speaker: Kelsey Weigel, PhD, Scientist II,...
WORLD CB AND CDX BOSTON 2019 (CLINICAL BIOMARKER AND COMPANION DIAGNOSTICS)September 9-12, 2019 The Renaissance Boston Waterfront, Boston, MA Flagship Biosciences is a proud Spotlight Partner of World CB and CDx Boston 2019. Flagship’s leaders will be speaking and...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Introduction and BackgroundAdam Beharry, PhD, is a Flagship scientist who describes his work as applying advanced technical knowledge and critical thinking to expand Flagship’s tissue image analysis in neuromuscular and rare diseases. Adam’s degrees include: BS –...
IntroductionThe success of clinical trials is highly dependent on the intricacies of patient recruitment. Other challenges, from the costs of clinical supplies to the specific procedural requirements that can extend physicians’ time, can increase costs. There are also...
Broomfield, CO – June 1, 2021 – Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that the company has moved its headquarters to a new location in Broomfield, Colorado, just north of Denver. The office, at 11800 Ridge...
PUBLICATIONS/POSTERS
Key takeaways Building Predictive Models of Clinical Outcomes in Immune Oncology Using Computational Tissue Analysis Scorecards The spatial location of PD-L1 expression can identify patients who will likely respond to anti-PD-1/PD-L1 therapy Flagship’s unique spatial...
Artificial intelligence (AI) systems for pathology may appear to compete with manual pathology, as they enable the assessment of thousands of cells and application of complex scoring schemes beyond the capacity of a human pathologist. However, this technology...
CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry review. “The ease of leveraging Flagship’s powerful solution is yet another massive...